Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
复制标题
DOI：
10.1155/2022/3098527
复制
发表时间：
2022
影响因子：
2.6
通讯作者：
Arnuntasupakul, Vanlapa
中科院分区：
文献类型：
--
作者：
Surapat, Bhitta;Kobpetchyok, Warissa;Kiertiburanakul, Sasisopin;Arnuntasupakul, Vanlapa
在住院容量有限的情况下，利用酒店作为轻症患者的延伸医疗设施，发展了“医院”。本研究检查了在泰国医院接受法维匹拉韦（治疗 COVID-19 的主要药物）治疗的 2019 年冠状病毒病 (COVID-19) 患者的临床证据。 我们回顾性收集了 2021 年 4 月 27 日至 2021 年 7 月 2 日入住医院期间接受法匹拉韦治疗 COVID-19 的所有患者的人口统计和临床信息、药物治疗和结果数据。分析了无法在医院完成治疗和需要转院的成人的危险因素。 该研究总共纳入了 421 名患者。大多数患者（94.5%）接受法匹拉韦治疗 COVID-19 肺炎。 42.3% 的患者接受了辅助皮质类固醇治疗。就治疗结果而言，83.6%的患者在医院完成治疗，仅发生2例死亡。未观察到严重的药物不良反应。多变量分析中，年龄（优势比（OR） = 1.06；95%置信区间（CI） = 1.02–1.10，P=0.002）、呼吸困难（OR = 2.84；95% CI = 1.25–6.44，P=0.013）、味觉丧失（OR = 107.63；95% CI = 1.24–9337.39，P=0.040）、皮质类固醇使用（OR = 12.56；95% CI = 3.65–43.18，P < 0.001）以及法匹拉韦使用时间延长（OR = 16.91；95% CI = 7.29–39.24，P < 0.001）与较高的转院风险相关。 在医院接受法匹拉韦治疗的轻至中度 COVID-19 患者中，观察到转院率和死亡率较低。老年患者、呼吸困难或味觉丧失的患者以及接受 10 天法匹拉韦疗程或辅助皮质类固醇治疗的患者可能需要谨慎，因为这些患者可能需要在医院接受进一步治疗。
In a setting with a limited capacity for hospitalization, “hospitels” have been developed by using hotels as extension healthcare facilities for patients with mild illness. This study examined the clinical evidence of patients with coronavirus disease 2019 (COVID-19) who were treated with favipiravir, the main medication for treating COVID-19, in the hospitel setting in Thailand. We retrospectively collected demographic and clinical information, medication treatment, and outcome data for all patients who received favipiravir for COVID-19 during admission to a hospitel from April 27, 2021, to July 2, 2021. Risk factors for adults who could not complete treatment in a hospitel and who required hospitel transfer were analyzed. In total, 421 patients were included in the study. Most patients (94.5%) received favipiravir to treat COVID-19 pneumonia. Adjunctive corticosteroids were prescribed to 42.3% of patients. Concerning the treatment outcome, 83.6% of patients completed treatment at a hospitel, and only two deaths occurred. No serious adverse drug reactions were observed. On multivariate analysis, age (odds ratio (OR) = 1.06; 95% confidence interval (CI) = 1.02–1.10, P=0.002), dyspnea (OR = 2.84; 95% CI = 1.25–6.44, P=0.013), loss of taste (OR = 107.63; 95% CI = 1.24–9337.39, P=0.040), corticosteroid use (OR = 12.56; 95% CI = 3.65–43.18, P < 0.001), and an extended duration of favipiravir use (OR = 16.91; 95% CI = 7.29–39.24, P < 0.001) were associated with a higher risk of hospitel transfer. Low rates of hospitel transfer and mortality were observed in mild-to-moderate COVID-19 patients treated with favipiravir at hospitel. Caution might be required in elderly patients, patients with dyspnea or a loss of taste, and patients receiving a 10-day course of favipiravir or adjunctive corticosteroids because these patients might require further management in the hospitel.
登录
查看更多内容
影响因子：
13.6
作者：
Bergman J;Ballin M;Nordström A;Nordström P
通讯作者：
Nordström P
影响因子：
11.8
作者：
Vahey GM;Marshall KE;McDonald E;Martin SW;Tate JE;Midgley CM;Killerby ME;Kawasaki B;Herlihy RK;Alden NB;Staples JE;Colorado Investigation Team2
通讯作者：
Colorado Investigation Team2
影响因子：
3.3
作者：
Sivakorn, Chaisith;Luvira, Viravarn;Iamsirithaworn, Sopon
通讯作者：
Iamsirithaworn, Sopon
DOI：
10.1016/j.mjafi.2020.08.004
发表时间：
2020-10-01
期刊：
Medical journal, Armed Forces India
影响因子：
--
作者：
Agrawal, Umang;Raju, Reyma;Udwadia, Zarir F
通讯作者：
Udwadia, Zarir F
影响因子：
3.7
作者：
Manabe T;Kambayashi D;Akatsu H;Kudo K
通讯作者：
Kudo K